This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
I had written a reply contradicting post #89 and deleted it. Here is what survived.
Anticoagulant questions come up regularly and are the clearest case for professional advice rather than discussion, because the consequence of being wrong is not gradual.
Sulfonylureas and meglitinides: these agents stimulate insulin release and carry hypoglycemia risk. Combining them with semaglutide or tirzepatide requires dose adjustment of the secretagogue and close monitoring. The combination is not contraindicated but requires active management.
Not the whole picture, but the part of it I can speak to.
Coming back to post #94, because the follow-up matters more than the original answer.
The strongest argument against my own position on Warfarin and altered intake, stated as well as I can state it, since nobody else has yet.
Gastrointestinal symptoms from one compound can mask or mimic an interaction with another. Introducing two changes at once makes attribution impossible, which is an argument for spacing them.
Happy to be the one who is wrong here if it settles the question.
The practical version of Warfarin and altered intake is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
A supplement is a drug for interaction purposes, and the fact that it is sold without a prescription tells you nothing about whether it interacts. The paperwork is usually worse rather than better.
I would want the raw data before agreeing with my own summary of it.
Answering the Warfarin and altered intake question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.
I read post #101 twice before replying, because I had assumed the opposite.
Anticoagulants: no direct interaction with the compounds in this class. Weight loss and body composition changes might affect the clearance or effect of warfarin if you are on it; monitoring INR more frequently during weight loss is reasonable.
The general case is well covered; this is the awkward specific one.
Thank you — that answers what I came here to find out.
Reading back through the Warfarin and altered intake threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.
Gastrointestinal symptoms from one compound can mask or mimic an interaction with another. Introducing two changes at once makes attribution impossible, which is an argument for spacing them.
I have written this out at length because the short version keeps being misread.
On post #106 — agreed on the reasoning, with one qualification.
Warfarin and altered intake is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
The honest answer on Warfarin and altered intake is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.
Most people get the first two right and then argue about the fourth.
Coming back to post #110, because the follow-up matters more than the original answer.
The bit of Warfarin and altered intake that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.
I have three months of notes on Warfarin and altered intake and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
Post #116 answers the question as asked. The question underneath it is different.
Reframing Warfarin and altered intake slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
That reframing is the whole thing. The facts I already had.
Answering the question post #119 raises rather than the one it answers.
Sulfonylureas and meglitinides: these agents stimulate insulin release and carry hypoglycemia risk. Combining them with semaglutide or tirzepatide requires dose adjustment of the secretagogue and close monitoring. The combination is not contraindicated but requires active management.